Publications

• Walburn J, Sarkany RPE. Quality of life in the photodermatoses: the hidden toll of photosensitivity. Br J Dermatol. 2020;182:1077.

• Fajuyigbe D, Douki T, van Dijk A, Sarkany RP, Young AR. Dark cyclobutane pyrimidine dimers are formed in the epidermis of Fitzpatrick skin types I/II and VI in vivo after exposure to solar simulated radiation. Pigment Cell Melanoma Res. 2020 Dec 26. doi: 10.1111/pcmr.12956. Epub ahead of print. PMID: 33369222.

• Canfield M, Norton S, Walburn J, Morrison-Bowen N, Sainsbury K, Araujo-Soares V, Sarkany R, Weinman J. Facial photoprotection in xeroderma pigmentosum (XP) patients: Validation of a new self-reported questionnaire of adherence. Photodermatol Photoimmunol Photomed. 2020;36:118-125.

• Harte J, Chapagain A, Sarkany RPE, Chaudhri S. The Case | Bullous eruptions in end-stage renal failure. Kidney Int. 2020;97:1067-1068.

• Walburn J, Canfield M, Norton S, Sainsbury K, Araújo-Soares V, Foster L, Berneburg M, Sarasin A, Morrison-Bowen N, Sniehotta FF, Sarkany R, Weinman J. Psychological correlates of adherence to photoprotection in a rare disease: International survey of people with Xeroderma Pigmentosum. Br J Health Psychol. 2019;24:668-686

• Walburn J, Norton S, Sarkany R, Sainsbury K, Araújo-Soares V, Morgan M, Canfield M, Foster L, Heydenreich J, McCrone P, Mander A, Sniehotta FF, Wulf HC, Weinman J. Evaluation of a personalised adherence intervention to improve photoprotection in adults with Xeroderma Pigmentosum (XP): protocol for the trial of XPAND. BMJ Open. 2019;9:e028577. doi: 10.1136/bmjopen-2018-028577.

• Cohen JI, Manoli I, Dowdell KC, Krogmann TA, Tamura D, Radecki P, Bu W, Turk SP, Liepshutz K, Hornung RL, Fassihi H, Sarkany RP, Bonnycastle LL, Chines PS, Swift AJ, Myers TG, Levoska MA, DiGiovanna JJ, Collins FS, Kraemer KH, Pittaluga S, Jaffe ES. Hydroa vacciniforme-like lymphoproliferative disorder: an EBV disease with a low risk of systemic illness in Caucasians. Blood. 2019 May 7. Doi: 10.1182/blood.2018893750. [Epub ahead of print]

• Morgan M, Anderson R, Walburn J, Weinman J, Sarkany R. The influence of perceived medical risks and psychosocial concerns on photoprotection behaviours among adults with xeroderma pigmentosum: a qualitative interview study in the UK. BMJ Open. 2019;9:e024445. doi: 10.1136/bmjopen-2018-024445.

• Lawrence KP, Douki T, Sarkany RPE, Acker S, Herzog B, Young AR. The UV/Visible Radiation Boundary Region (385-405 nm) Damages Skin Cells and Induces "dark" Cyclobutane Pyrimidine Dimers in Human Skin in vivo. Sci Rep. 2018; 8:12722.

• Fajuyigbe D, Coleman A, Sarkany RPE, Young AR, Schmalwieser AW. Diffuse Reflectance Spectroscopy as a Reliable Means of Comparing Ultraviolet Radiation-induced Erythema in Extreme Skin Colors. Photochem Photobiol. 2018;94:1066-1070.

• Fajuyigbe D, Lwin SM, Diffey BL, Baker R, Tobin DJ, Sarkany RPE, Young AR. Melanin distribution in human epidermis affords localized protection against DNA photodamage and concurs with skin cancer incidence difference in extreme phototypes. FASEB J. 2018;32:3700-3706.

• Young AR, Greenaway J, Harrison GI, Lawrence KP, Sarkany R, Douki T, Boyer F, Josse G, Questel E, Monteil C, Rossi AB. Sub-optimal Application of a High SPF Sunscreen Prevents Epidermal DNA Damage in Vivo. Acta Derm Venereol. 2018;98:880-887.

• Sainsbury K, Vieira R, Walburn J, Sniehotta FF, Sarkany R, Weinman J, Araujo-Soares V. Understanding and predicting a complex behavior using n-of-1 methods: Photoprotection in xeroderma pigmentosum. Health Psychol. 2018;37:1145-1158.

• Fityan A, McGibbon D, Fassihi H, Sarkany R. Paediatric solar urticaria: a case series. Br J Dermatol. 2018;178:1453-1454.

• Chee SN, Novakovic L, Fassihi H, Garibaldinos T, Sarkany R Chronic actinic dermatitis: successful treatment with psoralen-ultraviolet A photochemotherapy. Br J Dermatol. 2018;178:e189-e190.

• Tewari A, Fityan A, Fassihi H, Sarkany R. Solar urticaria developing in patients with erythropoietic protoporphyria: a clue to the pathogenesis of solar urticaria? Br J Dermatol. 2018;178:567-568.

• Abeti R, Zeitlberger A, Peelo C, Fassihi H, Sarkany RPE, Lehmann AR, Giunti P. Xeroderma pigmentosum: overview of pharmacology and novel therapeutic strategies for neurological symptoms. Br J Pharmacol. 2018 . doi: 10.1111/bph.14557. [Epub ahead of print] Review.

• Trokoudes D, Banerjee P, Fityan A, Sarkany R, White IR, White JM, McFadden JP. Photoaggravated contact dermatitis caused by methylisothiazolinone. Contact Dermatitis. 2017;76:303-304.

• Walburn J, Sarkany R, Norton S, Foster L, Morgan M, Sainsbury K, Araújo-Soares V, Anderson R, Garrood I, Heydenreich J, Sniehotta FF, Vieira R, Wulf HC, Weinman J. An investigation of the predictors of photoprotection and UVR dose to the face in patients with XP: a protocol using observational mixed methods. BMJ Open. 2017;7:e018364.

• Sebaratnam DF, Sarkany RPE, Fassihi H. A 'spot' diagnosis. Arch Dis Child Educ Pract Ed. 2017;102:220-221

• Garcia-Moreno H, Fassihi H, Sarkany RPE, Phukan J, Warner T, Lehmann AR, Giunti P. Xeroderma pigmentosum is a definite cause of Huntington's disease-like syndrome. Ann Clin Transl Neurol. 2017;5:102-108.

• Momen S, Sarkany R. Are very high cumulative doses of narrowband UVB safe in vitiligo?. Photodermatol Photoimmunol Photomed. 2017;33: 220-221.

• Sethi M, Haque S, Fawcett H, Wing JF, Chandler N, Mohammed S, Frayling IM, Norris PG, McGibbon D, Young AR, Sarkany RP, Lehmann AR, Fassihi H. A Distinct Genotype of XP Complementation Group A: Surprisingly Mild Phenotype Highly Prevalent in Northern India/Pakistan/Afghanistan. J Invest Dermatol. 2016;136:869-72.

• Fityan A, Fassihi H, Sarkany R. Congenital erythropoietic porphyria: mild presentation with late onset associated with a mutation in the UROS gene promoter sequence. Clin Exp Dermatol. 2016;41:953-954

• Tewari A, Grys K, Kollet J, Sarkany R, Young AR. Upregulation of MMP12 and its activity by UVA1 in human skin: potential implications for photoaging. J Invest Dermatol. 2014;134:2598-609.

• Tewari A, Grage MM, Harrison GI, Sarkany R, Young AR. UVA1 is skin deep: molecular and clinical implications. Photochem Photobiol Sci. 2013;12:95-103.

• Sethi M, Lehmann AR, Fawcett H, Stefanini M, Jaspers N, Mullard K, Turner S, Robson A, McGibbon D, Sarkany R, Fassihi H. Patients with xeroderma pigmentosum complementation groups C, E and V do not have abnormal sunburn reactions. Br J Dermatol. 2013;169:1279-87.

• Kashiyama K, Nakazawa Y, Pilz DT, Guo C, Shimada M, Sasaki K, Fawcett H, Wing JF, Lewin SO, Carr L, Li TS, Yoshiura K, Utani A, Hirano A, Yamashita S, Greenblatt D, Nardo T, Stefanini M, McGibbon D, Sarkany R, Fassihi H, Takahashi Y, Nagayama Y, Mitsutake N, Lehmann AR, Ogi T. Malfunction of Nuclease ERCC1-XPF Results in Diverse Clinical Manifestations and Causes Cockayne Syndrome, Xeroderma Pigmentosum, and Fanconi Anemia. Am J Hum Genet. 2013;92:807-19.

• Gonçalo M, Ferguson J, Bonevalle A, Bruynzeel DP, Giménez-Arnau A, Goossens A, Kerr A, Lecha M, Neumann N, Niklasson B, Pigatto P, Rhodes LE, Rustemeyer T, Sarkany R, Thomas P, Wilkinson M. Photopatch testing: recommendations for a European photopatch test baseline series. Contact Dermatitis. 2013;68:239-43.

• Kerr AC, Ferguson J, Attili SK, Beattie PE, Coleman AJ, Dawe RS, Eberlein B, Goulden V, Ibbotson SH, Menage H du P, Moseley H, Novakovic L, Walker SL, Woods JA, Young AR, Sarkany RP . Ultraviolet A1 phototherapy: a British Photodermatology Group workshop report. Clin Exp Dermatol. 2012 37:219-26.

• Sarkany R. Congenital erythropoietic porphyria: bringing evidence-based practice to a rare disease. Br J Dermatol. 2012;167:709.

• Agius E and Sarkany R. Thalidomide in 2nd Edition Handbook of Systemic Drug Treatment in Dermatology, Manson Publishing, 2012.

• Sarkany RP. Photopatch testing comes of age. Br J Dermatol. 2012 166:912-3. (Commentary)

• Stein PE, Badminton MN, Barth JH, Rees DC, Sarkany R, Stewart MF, Cox TM. Acute intermittent porphyria: fatal complications of treatment (lesson of the month) Clinical Medicine, 12: 293-4 (2012)

• Tewari A, Marsden J, Naik H, Benton EC, Sarkany R. Oral cholestyramine is not an effective treatment for uncomplicated erythropoietic protoporphyria. J Am Acad Dermatol. 2012;67:1383-4.

• Tewari A, Sarkany RP, Young AR. UVA1 induces cyclobutane pyrimidine dimers but not 6-4 photoproducts in human skin in vivo. J Invest Dermatol. 2012 132:394-400.

• Tewari A, Lahmann C, Sarkany R, Bergemann J, Young AR.Human erythema and matrix metalloproteinase-1 mRNA induction, in vivo, share an action spectrum which suggests common chromophores. Photochem Photobiol Sci. 2012;11:216-23.

• Byrne M, Stefanato CM, Sarkany R. A photosensitive pseudolymphomatous eruption. Actinic reticuloid (AR). Clin Exp Dermatol. 2012;37:203-4

• Penny H, Frame S, Dickinson F, Garrett G, Young AR, Sarkany R, Chitalia N, Hampson G, Goldsmith D. Determinants of vitamin D status in long-term renal transplant patients. Clin Transplant. 2012 26:E617-23.

• Sarkany PE, et al. Erythropoietic Uroporphyria Associated with Myeloid Malignancy Is Likely Distinct from Autosomal Recessive Congenital Erythropoietic Porphyria. Journal of Investigative Dermatology 131, 1172-1175 (2011).

• Jiun-Yit Pan and Robert P.E. Sarkany (2011). A Comparison of NB-UVB and PUVA in the Treatment of Vitiligo, Vitiligo - Management and Therapy, Kelly KyungHwa Park and Jenny Eileen Murase (Ed.), ISBN: 978-953-307-731-4, InTech, Available from: http://www.intechopen.com/articles/show/title/a-comparison-of-nb-uvb-and-puva-in-the-treatment-of-vitiligo

• Natkunarajah J, Gordon K, Chow J, Sarkany R, Millington GW, Marsden RA. Photoaggravated Sweet's syndrome. Clin Exp Dermatol. 2010;35:18-9.

• Almaani N, Robson A, Sarkany R, Griffiths WA. Erythema gyratum repens associated with pityriasis rubra pilaris. Clin Exp Dermatol. 2011;36:161-4.

• Sarkany R. Clinical implications of advances in understanding the inheritance of erythropoietic protoporphyria. Br J Dermatol. 2010;162:1156-7.

• Abbott RA, Calonje E, Grattan CE, Kurwa H, Sarkany RP. Yellow papules and plaques on the face of a young girl. Clin Exp Dermatol. 2009;34:745-6.

• Akhras V, Sarkany R, Walsh S, Hyde N, Marsden RA. Superficial granulomatous pyoderma treated preoperatively with infliximab. Clin Exp Dermatol. 2009;34:183-5.

• Wain EM, Mellerio JE, Stefanato CM, Sarkany R. Generalized pustular eruption in a 5-year-old boy. Clin Exp Dermatol. 2008;33:79-80.

• Jong CT, Finlay AY, Pearse AD, Kerr AC, Ferguson J, Benton EC, Hawk JL, Sarkany RP, McMullen E, Rhodes LE, Farr PM, Anstey AV.. The quality of life of 790 patients with photodermatoses. Br J Dermatol. 2008;159:192-7.

• Coleman A, Sarkany R, Walker S. Clinical ultraviolet dosimetry with a CCD monochromator array spectroradiometer. Phys Med Biol. 2008;53:5239-55.

• Fassihi H, Sarkany R. TL01 therapy for vitiligo. Brit Med J 334:1064 2007

• Ross GL, Chong H, Collyns T, Gascoyne-Binzi DM, Sarkany RP. Lichen scrofulosorum caused by Mycobacterium szulgai: a new cause of a tuberculide reaction. Br J Dermatol. 2007;156:586-7

• Crouch R, Akhras V, Sarkany R. Schnitzler's syndrome: successful treatment with anakinra. Australas J Dermatol. 2007;48:178-81.

• Sarkany RPE, Ross G, Willis F. Acquired Erythropoietic protoporphyria as a result of myelodysplasia causing loss of chromosome 18. Br J Dermatol. 155:464-6 (2006).

• Peters T and Sarkany RPE. Porphyria for the General Physician. Clin Med 5:275-281 (2005)

• Haydar AA, Hujairi N, Chowdhury P, Pattison J, Deacon A, Sarkany R, Goldsmith DJ. What's in a blister? A diagnostic twister. Nephrol Dial Transplant. 2004;19:1321-2.

• Morris S, Elder G, Hawk J, Sarkany RPE. Ferrochelatase gene polymorphism analysis for accurate genetic counselling in erythropoietic protoporphyria. Br J Dermatol. 147:572-4 (2002)

• Sarkany RPE. A memorable patient: a nasty surprise. Clin Exp Dermatol. 27:537-8 (2002)

• Sarkany R.P.E. Erythropoietic Protoporphyria (EPP) at 40: where are we now? Photodermatol Photoimmunol Photomed 18:147-52 (2002)

• Sarkany R.P.E. The management of porphyria cutanea tarda. Clin Exp Dermatol 26:225-232 (2001)

• Sarkany RPE. The porphyrias: a practical guide. Dermatology in Practice 9:6-9 (2001)

• Sarkany R.P.E. Porphyria: from Sir Walter Raleigh to molecular biology. Rheumaderm: current issues in rheumatology and dermatology. Ed. Mallia C and Uitto J. Advances in Experimental Medicine and Biology 455: 235-241 (1999)

• Sarkany RPE, Anstey A, Diffey BL et al. Home phototherapy: report on a workshop of the British Photodermatology Group, December 1996. Brit J Dermatol 140:195-199 (1999)

• Cox TM, Alexander GJM and Sarkany RPE. Protoporphyria. Seminars in Liver Disease; 18: 85-93 (1998)

• Sarkany RPE, Monk BE, Handfield-Jones SE. Telangiectasia macularis eruptiva perstans: a case report and review of the literature. Clin. Exp. Dermatol. 23: 28-39 (1998)

• Sarkany RPE, Burrows NP, Grant JW, Pye RJ and Norris PG. The pustular eruption of ulcerative colitis: a variant of Sweet’s syndrome? Brit J Dermatol 138:365-6 (1998).

• Sarkany RPE and Cox TM. Liver failure in erythropoietic protoporphyria. J. Am. Acad. Dermatol. 34: 540-1 (1996)

• Sarkany RPE. The inheritance of human erythropoietic protoporphyria. MD Thesis, University of London, 1995.

• Sarkany RPE and Cox TM. Autosomal recessive erythropoietic protoporphyria: a syndrome of severe photosensitivity and hepatic failure. Quart. J. Med. 88: 541-49 (1995)

• Sarkany RPE. The molecular genetics of erythropoietic protoporphyria. Current Opinion in Dermatology 219-224 (1995).

• Sarkany RPE, Whitcombe DM, Cox TM. Molecular characterization of a ferrochelatase gene defect causing anomalous RNA splicing in Erythropoietic Protoporphyria. J. Invest. Dermatol. 102: 481-4 (1994)

• Sarkany RPE, Alexander GJMA, Cox TM. Recessive inheritance of Erythropoietic Protoporphyria with liver failure. The Lancet 343: 1394-1396 (1994)

• Sarkany RPE and Norris PG. Hepatic complications of erythropoietic protoporphyria. Brit. J. Dermatol. 130: 258 (1994)

• Sarkany RPE and Moreland BH. Enhancement of the autocatalytic activation of trypsinogen to trypsin by bile and bile acids. Biochim. Biophys. Acta 839: 262-267 (1985)